Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:6/11/2009

including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
2. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
3. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
4. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
10. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
11. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v6klp2/nanobiotechnology ... PharmaBiotech,s new report "Nanobiotechnology Applications, Markets ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "DNA Sequencing - ... This report briefly reviews basics of ... their applications. Current large and small sequencers are ... applications of sequencing are described including those for ...
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form of ... special anti-vascular endothelial growth factor agents given by injection into the eye. Dry ... a scientific protocol for the many millions diagnosed with it. AMD usually starts ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ) ... "Gene Therapy - Technologies, Markets and Companies" ... therapy are difficult to estimate as there is only ... in China since 2004. Gene ... estimates are based on epidemiology of diseases to be ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2
... just escaped January a notoriously depressing month because ... dank weather thats no surprise. In fact, an ... ago) was the most depressing day of the year. ... burden because of the challenges they face, their depression ...
... A biotech company moving to Madison from Chicago is ... the state. , ,Governor Jim Doyle announced earlier this ... $135,000 from the Department of Commerce Technology Venture ... (TAG) programs to help the company purchase new equipment ...
... Madison-based lab that studies learning technologies with the University of Wisconsin ... Thursday evening at the World Futurist Society meeting . The ... experience at the Academic Advanced Distributed Learning Co-Lab , Brown ... is looking to video games as a teaching tool. Read more. ...
Cached Biology Technology:Post-January, tech entrepreneurs have reasons to be depressed 2Post-January, tech entrepreneurs have reasons to be depressed 3Post-January, tech entrepreneurs have reasons to be depressed 4Tech Digest: Futurists on learning; Sonic Foundry; Accu Tech; Fiserv 2
(Date:8/24/2015)... 2015 The consulting company Frost & ... manufacturer DERMALOG and its customized solutions and products for ... of the Year Award". DERMALOG is particularly successful with a ... -Cross reference: Picture is available at AP Images ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... show a combination of depressive symptoms and elevated levels of ... likely to develop major depression than those who show neither ... In a study published today in the Proceedings ... University of Cambridge have identified the first biomarker a ...
... non-coding RNAs can be used to predict if individuals ... Cancer Genome Atlas project. The results, which are published ... the levels of specific types of non-coding RNAs can ... These RNAs can also be used to classify cancer ...
... cancers so difficult to treat is that malignant cells from ... and blood vessels to invade new locations. Now, researchers have ... cancer by using a film of nanofibers thinner than human ... invading new areas, the migrating cells latch onto the specially-designed ...
Cached Biology News:First biological marker for major depression could enable better diagnosis and treatment 2First biological marker for major depression could enable better diagnosis and treatment 3First biological marker for major depression could enable better diagnosis and treatment 4Small non-coding RNAs could be warning signs of cancer 2Researchers hijack cancer migration mechanism to 'move' brain tumors 2Researchers hijack cancer migration mechanism to 'move' brain tumors 3Researchers hijack cancer migration mechanism to 'move' brain tumors 4
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
... utilize the membrane-permeant ester forms (CCF2-AM ... fluorescent beta-lactamase substrates, CCF2 and CCF4. ... cell, where cleavage by endogeneous cytoplasmic ... negatively charged forms, thereby trapping them ...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
... utilize the membrane-permeant ester forms (CCF2-AM ... fluorescent beta-lactamase substrates, CCF2 and CCF4. ... cell, where cleavage by endogeneous cytoplasmic ... negatively charged forms, thereby trapping them ...
Biology Products: